FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.
My team has been using the Anti-FMC63 Antibody, and they always have consistent and reliable data that is being used for preclinical IND-enabling studies as well as clinical studies. I recommend using AcroBiosystems for your antibody needs.
Our bioanalytical team have consistently obtained reliable CAR detection results using the PE‑labeled monoclonal anti‑FMC63 antibody in our animal studies. The antibody shows strong specificity, clear signal, and low background, with consistent performance across runs. Overall, it has been a dependable, high‑quality reagent, and we consider the vendor a reliable supplier for CAR detection assays.
The FM3-PY54A2 PE antibody from AcroBiosystems has proven to be an outstanding reagent for flow cytometry applications. It delivers exceptional signal clarity and consistency, providing optimal staining and reproducible results across multiple experimental runs. The antibody exhibits high specificity and minimal background, ensuring precise detection and reliable data quality.
Overall, this product demonstrates excellent performance and stability, making it a highly recommended choice for researchers seeking robust and accurate flow cytometry analysis.